Table 2.
TCR sequencing results in the tumor tissue, pre‐therapy and post‐cycle #4 blood samples
| Sample | DNA input (ng) | Total productive sequences | Unique productive sequences | CumFreq‐100 (%) | CumFreq‐25 (%) | Max‐Freq (%) | Productive clonality |
|---|---|---|---|---|---|---|---|
| Tumor tissue | 1611 (320–10 064) | 5400 (603–48 501) | 3172 (447–19 934) | 23.16 (3.82–66.67) | 11.10 (1.49–57.69) | 1.55 (0.12–10.26) | 0.048 (0.007–0.296) |
| PBMC Pre‐Rx | 2495 (1240–2535) | 46 512 (1 1189–218 764) | 29 048 (7231–87 967) | 19.31 (0.23–68.04) | 15.09 (0.09–63.49) | 3.02 (0.25–33.84) | 0.09 (0.01–0.47) |
| PBMC post‐cycle #4 | 2493 (976–2520) | 80 012 (1067–201 848) | 27 799 (930–89 150) | 18.30 (0.02–84.32) | 12.36 (0.02–77.53) | 2.56 (0.3–40.69) | 0.10 (0.01–0.54) |
Values are expressed as median (range).
CumFeq‐25, that of the most dominant 25 clonotypes; CumFreq‐100, the cumulative frequencies of the most dominant 100 clonotypes; Max‐Freq, the frequency of the most dominant clonotype, PBMC post‐cycle #4, peripheral blood mononuclear cells after four cycles of R‐CHOP; PBMC Pre‐Rx, peripheral blood mononuclear cells at diagnosis.